Adenovirus-mediated cancer gene therapy and virotherapy

Takuya Fukazawa, Junji Matsuoka, Tomoki Yamatsuji, Yutaka Maeda, Mary L. Durbin, Yoshio Naomoto

Research output: Contribution to journalReview articlepeer-review

56 Citations (Scopus)

Abstract

Gene therapy and virotherapy are among the approaches currently used to treat malignant tumors. Gene therapy and virotherapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/ or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area.

Original languageEnglish
Pages (from-to)3-10
Number of pages8
JournalInternational journal of molecular medicine
Volume25
Issue number1
DOIs
Publication statusPublished - 2010

Keywords

  • Adenovirus
  • Gene therapy
  • Specific promoter
  • Virotherapy

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'Adenovirus-mediated cancer gene therapy and virotherapy'. Together they form a unique fingerprint.

Cite this